What we do
The Snijder Lab is pioneering multiplexed image-based drug screening in patient biopsies, a technique we call pharmacoscopy, for both systems biology and personalized medicine. In an intervention trial, pharmacoscopy-guided treatments have shown promising improvements in patient outcome for blood cancers (Snijder et al., Lancet Haematology 2017). We now combine these functional drug response profiles with multi-OMICs integration and deep learning-based image analyses, aiming to identify the molecular and cellular systems that underly drug-response individuality and improve patient treatment.
Find out about the Group’s activities
